vs
Side-by-side financial comparison of ICU MEDICAL INC (ICUI) and LGI Homes, Inc. (LGIH). Click either name above to swap in a different company.
ICU MEDICAL INC is the larger business by last-quarter revenue ($540.7M vs $474.0M, roughly 1.1× LGI Homes, Inc.). LGI Homes, Inc. runs the higher net margin — 3.7% vs -2.9%, a 6.6% gap on every dollar of revenue. On growth, ICU MEDICAL INC posted the faster year-over-year revenue change (-14.1% vs -15.0%). Over the past eight quarters, LGI Homes, Inc.'s revenue compounded faster (10.1% CAGR vs -2.3%).
ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, a...
LGI Homes is a Texas-based builder of new construction homes and housing developments, with its development projects mostly focused in the southwestern region of the United States. According to Builder Magazine, LGI Homes is the tenth largest home builder in the United States. 2013, the company announced the pricing of its initial public offering: 9,000,000 shares at $11 per share. 2019, LGI Homes closed 7,690 homes, which was an 18.1% increase over 2018. Home sales revenue in 2019 was $1.8 b...
ICUI vs LGIH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $540.7M | $474.0M |
| Net Profit | $-15.7M | $17.3M |
| Gross Margin | 37.5% | 17.7% |
| Operating Margin | 1.0% | 3.9% |
| Net Margin | -2.9% | 3.7% |
| Revenue YoY | -14.1% | -15.0% |
| Net Profit YoY | 34.0% | -66.0% |
| EPS (diluted) | $-0.63 | $0.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $540.7M | $474.0M | ||
| Q3 25 | $537.0M | $396.6M | ||
| Q2 25 | $548.9M | $483.5M | ||
| Q1 25 | $604.7M | $351.4M | ||
| Q4 24 | $629.8M | $557.4M | ||
| Q3 24 | $589.1M | $651.9M | ||
| Q2 24 | $596.5M | $602.5M | ||
| Q1 24 | $566.7M | $390.9M |
| Q4 25 | $-15.7M | $17.3M | ||
| Q3 25 | $-3.4M | $19.7M | ||
| Q2 25 | $35.3M | $31.5M | ||
| Q1 25 | $-15.5M | $4.0M | ||
| Q4 24 | $-23.8M | $50.9M | ||
| Q3 24 | $-33.0M | $69.6M | ||
| Q2 24 | $-21.4M | $58.6M | ||
| Q1 24 | $-39.5M | $17.1M |
| Q4 25 | 37.5% | 17.7% | ||
| Q3 25 | 37.4% | 21.5% | ||
| Q2 25 | 37.9% | 22.9% | ||
| Q1 25 | 34.7% | 21.0% | ||
| Q4 24 | 36.1% | 22.9% | ||
| Q3 24 | 34.8% | 25.1% | ||
| Q2 24 | 34.8% | 25.0% | ||
| Q1 24 | 32.7% | 23.4% |
| Q4 25 | 1.0% | 3.9% | ||
| Q3 25 | 2.6% | 5.4% | ||
| Q2 25 | 1.9% | 8.2% | ||
| Q1 25 | 2.1% | 0.0% | ||
| Q4 24 | 6.0% | 8.2% | ||
| Q3 24 | 1.4% | 12.3% | ||
| Q2 24 | 1.3% | 11.2% | ||
| Q1 24 | -1.9% | 4.8% |
| Q4 25 | -2.9% | 3.7% | ||
| Q3 25 | -0.6% | 5.0% | ||
| Q2 25 | 6.4% | 6.5% | ||
| Q1 25 | -2.6% | 1.1% | ||
| Q4 24 | -3.8% | 9.1% | ||
| Q3 24 | -5.6% | 10.7% | ||
| Q2 24 | -3.6% | 9.7% | ||
| Q1 24 | -7.0% | 4.4% |
| Q4 25 | $-0.63 | $0.74 | ||
| Q3 25 | $-0.14 | $0.85 | ||
| Q2 25 | $1.43 | $1.36 | ||
| Q1 25 | $-0.63 | $0.17 | ||
| Q4 24 | $-0.97 | $2.15 | ||
| Q3 24 | $-1.35 | $2.95 | ||
| Q2 24 | $-0.88 | $2.48 | ||
| Q1 24 | $-1.63 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $1.7B |
| Stockholders' EquityBook value | $2.1B | $2.1B |
| Total Assets | $4.1B | $3.9B |
| Debt / EquityLower = less leverage | — | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $308.6M | $53.2M | ||
| Q3 24 | $312.5M | — | ||
| Q2 24 | $302.6M | — | ||
| Q1 24 | $251.4M | — |
| Q4 25 | — | $1.7B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.1B | $2.1B | ||
| Q3 25 | $2.1B | $2.1B | ||
| Q2 25 | $2.1B | $2.1B | ||
| Q1 25 | $2.0B | $2.0B | ||
| Q4 24 | $2.0B | $2.0B | ||
| Q3 24 | $2.0B | $2.0B | ||
| Q2 24 | $2.0B | $1.9B | ||
| Q1 24 | $2.1B | $1.9B |
| Q4 25 | $4.1B | $3.9B | ||
| Q3 25 | $4.1B | $4.0B | ||
| Q2 25 | $4.1B | $4.0B | ||
| Q1 25 | $4.2B | $3.9B | ||
| Q4 24 | $4.2B | $3.8B | ||
| Q3 24 | $4.3B | $3.8B | ||
| Q2 24 | $4.3B | $3.7B | ||
| Q1 24 | $4.3B | $3.5B |
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.73× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.6M | $86.8M |
| Free Cash FlowOCF − Capex | $36.0M | — |
| FCF MarginFCF / Revenue | 6.6% | — |
| Capex IntensityCapex / Revenue | 4.6% | 0.0% |
| Cash ConversionOCF / Net Profit | — | 5.01× |
| TTM Free Cash FlowTrailing 4 quarters | $91.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.6M | $86.8M | ||
| Q3 25 | $56.7M | $-13.2M | ||
| Q2 25 | $11.2M | $-86.4M | ||
| Q1 25 | $51.3M | $-127.1M | ||
| Q4 24 | $40.2M | $57.0M | ||
| Q3 24 | $36.1M | $-17.8M | ||
| Q2 24 | $82.0M | $-83.5M | ||
| Q1 24 | $45.8M | $-99.5M |
| Q4 25 | $36.0M | — | ||
| Q3 25 | $27.6M | $-13.3M | ||
| Q2 25 | $-8.5M | $-86.4M | ||
| Q1 25 | $36.7M | $-128.0M | ||
| Q4 24 | $16.1M | $56.4M | ||
| Q3 24 | $16.2M | $-17.8M | ||
| Q2 24 | $62.5M | $-83.8M | ||
| Q1 24 | $29.9M | $-100.5M |
| Q4 25 | 6.6% | — | ||
| Q3 25 | 5.1% | -3.3% | ||
| Q2 25 | -1.5% | -17.9% | ||
| Q1 25 | 6.1% | -36.4% | ||
| Q4 24 | 2.6% | 10.1% | ||
| Q3 24 | 2.7% | -2.7% | ||
| Q2 24 | 10.5% | -13.9% | ||
| Q1 24 | 5.3% | -25.7% |
| Q4 25 | 4.6% | 0.0% | ||
| Q3 25 | 5.4% | 0.0% | ||
| Q2 25 | 3.6% | 0.0% | ||
| Q1 25 | 2.4% | 0.2% | ||
| Q4 24 | 3.8% | 0.1% | ||
| Q3 24 | 3.4% | 0.0% | ||
| Q2 24 | 3.3% | 0.0% | ||
| Q1 24 | 2.8% | 0.3% |
| Q4 25 | — | 5.01× | ||
| Q3 25 | — | -0.67× | ||
| Q2 25 | 0.32× | -2.74× | ||
| Q1 25 | — | -31.83× | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | -0.26× | ||
| Q2 24 | — | -1.43× | ||
| Q1 24 | — | -5.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
LGIH
| West Reportable Segment | $128.2M | 27% |
| Southeast Reportable Segment | $118.9M | 25% |
| Central Reportable Segment | $105.8M | 22% |
| Florida Reportable Segment | $69.2M | 15% |
| Northwest Reportable Segment | $51.8M | 11% |
